Deal Watch: Bayer/CRISPR Link-up Highlights Spate Of Deals At Year-End
Executive Summary
Lilly is the latest established biopharma to license Halozyme's EXTENZE subcutaneous delivery technology. Mallinckrodt pays $175m up front to The Medicines Co. for a trio of topical hemostasis drugs.